A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment. The trial will be known as the ProScreen trial and is designed to enroll about 67,000 men aged between 55 […]![]()
